Literature DB >> 6240224

In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

M Peeters, E Van Dyck, P Piot.   

Abstract

The in vitro activities of the new spectinomycin analog U-63366 and four new quinolone derivatives, rosoxacin, norfloxacin, ofloxacin, and ciprofloxacin, were compared with those of penicillin, tetracycline, thiamphenicol, cefotaxime, ceftriaxone, and spectinomycin against 222 beta-lactamase-negative and 25 beta-lactamase-positive Neisseria gonorrhoeae strains. U-63366 was more active than spectinomycin, inhibiting 90% of the strains at a concentration of 2 mg/liter. Among the quinolone derivatives, ciprofloxacin was the most active compound in vitro (90% MIC, 0.002 mg/liter), followed by ofloxacin (90% MIC, 0.008 mg/liter), norfloxacin (90% MIC, 0.015 mg/liter), and rosoxacin (90% MIC, 0.03 mg/liter).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240224      PMCID: PMC179978          DOI: 10.1128/AAC.26.4.608

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Has clinical pharmacology lost its way?

Authors:  M Bonati; G Tognoni
Journal:  Lancet       Date:  1984-03-10       Impact factor: 79.321

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.

Authors:  C C Sanders
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

4.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

5.  A comparison of rosoxacin with ampicillin and probenecid in the treatment of uncomplicated gonorrhea.

Authors:  A I Cohen; M F Rein; R C Noble
Journal:  Sex Transm Dis       Date:  1984 Jan-Mar       Impact factor: 2.830

6.  Infections with non-penicillinase-producing Neisseria gonorrhoeae treated with cefuroxime: treatment failures.

Authors:  D de Hoop; K C Nayyar; B van Klingeren; E Stolz; M F Michel
Journal:  Sex Transm Dis       Date:  1982 Oct-Dec       Impact factor: 2.830

7.  Treatment of uncomplicated gonorrhea with rosoxacin.

Authors:  H H Handsfield; F N Judson; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

8.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

9.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

10.  Treatment of uncomplicated gonorrhoea in women. Comparison of rosoxacin and spectinomycin.

Authors:  O V Calubiran; L B Crisologo-Vizconde; T E Tupasi; C A Torres; B M Limson
Journal:  Br J Vener Dis       Date:  1982-08
View more
  22 in total

1.  In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens.

Authors:  W R Bowie; C E Shaw; D G Chan; J Boyd; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

2.  Norfloxacin in the therapy of uncomplicated gonorrhea.

Authors:  B Romanowski; H Wood; J Draker; M C Tsianco
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

3.  In vitro susceptibilities of oral pigmented Bacteroides species to trospectomycin and other selected antimicrobial agents.

Authors:  C C Johnson; M Wendeler; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

Authors:  K H Tjiam; J H Wagenvoort; B van Klingeren; P Piot; E Stolz; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

5.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

6.  Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species.

Authors:  N V Jacobus; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  In vitro antimicrobial sensitivity of Neisseria gonorrhoeae from Rwanda.

Authors:  J Bogaerts; J Vandepitte; E Van Dyck; R Vanhoof; M Dekegel; P Piot
Journal:  Genitourin Med       Date:  1986-08

8.  Mild and convenient N-formylation protocol in water-containing solvents.

Authors:  Bilal A Aleiwi; Katsuhiko Mitachi; Michio Kurosu
Journal:  Tetrahedron Lett       Date:  2013-04-17       Impact factor: 2.415

Review 9.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

Review 10.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.